Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study

BMC Neurology

Table 3 Relative risks and HR calculation by investigated variables

Variable	RR (CI)°	HR	p
Model A
Sex (men/women)	0.78 (0.28–2.22)	1.24 (0.43–3.56)	0.69
Age at MS onset^a	1.001 (0.97–1.03)	1.05 (1.01–1.10)	0.03
Follow-up length^a	1.03 (0.98–1.08)	_	_
IS exposure (yes vs. no)^b	4.01 (1.14–14.1)	11.05 (1.67–73.3)	0.013
Model B
Sex		1.32 (0.46–3.78)	0.6
Age at treatment^a		1.07 (1.02–1.12)	0.01
Disease duration^a		2.36 (0.71–7.84)	0.2
IS exposure (yes vs. no)^b		35.05 (3.12–403.31)	0.01

^aAge at onset and length of follow-up were dichotomous variables according to the median of the distribution in the whole cohort in univariate analyses, while they were calculated as continuous variables in Cox models
^bModel B was built including age at treatment initiation (IS or other therapies) and disease duration as covariates

ISSN: 1471-2377